Pancreatic Cancer Research

ResearcherShandong University of Traditional Chinese MedicineActive in the last 2 years

Xianbin Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0948-6698; OpenAlex author ID A5086619845. Sources: OpenAlex.

Their work

Papers
20 (first author 2, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
32
Papers, trials and grants by year

2018: 3 papers · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: 2 papers · 2023: 4 papers · 2024: 3 papers · 2025: 2 papers · 2026: 1 paper

Papers 20

  1. Global and regional disparities in the burden of disease and risk factors between pancreatitis and pancreatic cancer: a systematic analysis for the global burd… Last author DOI 10.1186/s12876-026-04668-x↗
  2. A novel BCAT1 inhibitor bufalin sensitizes pancreatic cancer cells to chemotherapy. Co-author DOI 10.1016/j.gendis.2024.101503↗
  3. Identification of USP39 as a prognostic and predictive biomarker for determining the response to immunotherapy in pancreatic cancer. Co-author DOI 10.1186/s12885-025-14096-x↗
  4. Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance. Last author DOI 10.1007/s10555-023-10125-y↗
  5. SKP2 promotes the metastasis of pancreatic ductal adenocarcinoma by suppressing TRIM21-mediated PSPC1 degradation. Last author DOI 10.1016/j.canlet.2024.216733↗
  6. Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile and drug/nanotherapeutic approaches. Last author DOI 10.1016/j.envres.2023.117443↗
  7. Cell membrane-camouflaged bufalin targets NOD2 and overcomes multidrug resistance in pancreatic cancer. Last author DOI 10.1016/j.drup.2023.101005↗
  8. Combined chemotherapy based on bioactive black phosphorus for pancreatic cancer therapy. First author DOI 10.1016/j.jconrel.2022.12.054↗
  9. A bioinformatics analysis, pre-clinical and clinical conception of autophagy in pancreatic cancer: Complexity and simplicity in crosstalk. Last author DOI 10.1016/j.phrs.2023.106822↗
  10. Identification of a New m6A Regulator-Related Methylation Signature for Predicting the Prognosis and Immune Microenvironment of Patients with Pancreatic Cancer. Co-author DOI 10.1155/2023/5565054↗
  11. Development of a Transcription Factor-Based Prognostic Model for Predicting the Immune Status and Outcome in Pancreatic Adenocarcinoma. Co-author DOI 10.1155/2022/4946020↗
  12. Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism. Co-author DOI 10.1371/journal.pone.0266601↗
  13. PIK3CB is involved in metastasis through the regulation of cell adhesion to collagen I in pancreatic cancer. Co-author DOI 10.1016/j.jare.2021.02.002↗
  14. Benefits of non-invasive methods compared to telemetry for distress analysis in a murine model of pancreatic cancer. Co-author DOI 10.1016/j.jare.2019.09.002↗
  15. The landscape of immune cell infiltration and its clinical implications of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.jare.2020.03.009↗
  16. Metformin and LW6 impairs pancreatic cancer cells and reduces nuclear localization of YAP1. Co-author DOI 10.7150/jca.33029↗
  17. LW6 enhances chemosensitivity to gemcitabine and inhibits autophagic flux in pancreatic cancer. Co-author DOI 10.1016/j.jare.2019.04.006↗
  18. α-cyano-4-hydroxycinnamate impairs pancreatic cancer cells by stimulating the p38 signaling pathway. Co-author DOI 10.1016/j.cellsig.2018.03.015↗
  19. Pancreaticoduodenectomy is justified in a subset of elderly patients with pancreatic ductal adenocarcinoma: A population-based retrospective cohort study of 4,… First author DOI 10.1016/j.ijsu.2018.03.054↗
  20. Blocking Autophagy in Cancer-Associated Fibroblasts Supports Chemotherapy of Pancreatic Cancer Cells. Co-author DOI 10.3389/fonc.2018.00590↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Milad Ashrafizadeh · 6 shared papers, 2023–2025 · strength 1.36
  2. Peng Gong · 8 shared papers, 2018–2023 · strength 1.17
  3. Jiahui Yuan · 3 shared papers, 2023–2025 · strength 0.66
  4. Dietmar Zechner · 6 shared papers, 2018–2022 · strength 0.66
  5. Brigitte Vollmar · 6 shared papers, 2018–2022 · strength 0.66
  6. Simone Kumstel · 6 shared papers, 2018–2022 · strength 0.66
  7. Peng Gong · 3 shared papers, 2020–2025 · strength 0.57
  8. Pingping Zhang · 2 shared papers, 2024–2025 · strength 0.51
  9. Mikiyas Amare Getu · 1 shared paper, 2026 · strength 0.43
  10. Edgar Heinz Uwe Wendt · 3 shared papers, 2018–2022 · strength 0.34
  11. Maria Schönrogge · 3 shared papers, 2018–2022 · strength 0.31
  12. Yongcheng Su · 1 shared paper, 2025 · strength 0.30
  13. Peng Gong · 1 shared paper, 2025 · strength 0.30
  14. Zhenli Guo · 1 shared paper, 2024 · strength 0.26
  15. Wei Zhang · 1 shared paper, 2025 · strength 0.25
  16. Tianle Zou · 1 shared paper, 2023 · strength 0.20
  17. Wenhua Zhou · 1 shared paper, 2023 · strength 0.19
  18. Shengyong Geng · 1 shared paper, 2023 · strength 0.19
  19. Weiguang Li · 1 shared paper, 2023 · strength 0.15
  20. Wei Zhang · 1 shared paper, 2023 · strength 0.15
  21. Tim Schreiber · 1 shared paper, 2022 · strength 0.14
  22. Masafumi Nakamura · 1 shared paper, 2021 · strength 0.12
  23. Biao Zheng · 1 shared paper, 2021 · strength 0.12
  24. Kenoki Ohuchida · 1 shared paper, 2021 · strength 0.12
  25. Jianhua Qu · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.